ACU Stock Surges on Q2 2026 Earnings Beat Driven by MyMedic Acquisition and Margin Recovery

• Acme United (ACU) reported Q2 2026 EPS of $1.22, significantly beating estimates of $0.81, driven by a 16% YoY sales increase from the MyMedic acquisition and organic growth of 8%.
• Gross margins expanded to 42.6% from 41.0% in the prior year, reflecting improved pricing power and cost efficiencies as the company transitions inventory to mitigate tariff pressures.
• The stock surged approximately 11.92% to 17.52% following the release, nearing its 52-week high, as management anticipates continued margin recovery and strong Q4 profitability driven by seasonal demand.
• Investors should monitor key risks including elevated SG&A expenses at 32% of sales, tariff and freight cost fluctuations, currency headwinds, and uneven geographic performance, particularly in Canada.

Acme United Corporation (ACU) delivered robust second-quarter 2026 financial results, significantly surpassing analyst expectations on both earnings per share and revenue metrics. The company reported earnings per share of $1.22 against a consensus estimate of $0.81, representing a 50.62% surprise.

Revenue reached $62.72 million, exceeding forecasts of $58.08 million by nearly 8%. The stock reacted positively to the announcement, surging between 11.92% and 17.52% to approach its 52-week high.

This outperformance highlights strong operational momentum and effective strategic execution during a period of broader economic uncertainty. The company's ability to navigate supply chain challenges while expanding its product portfolio has been a key driver of this positive market reaction.

How Is the MyMedic Acquisition Impacting Acme United's Growth?

The primary driver of Acme United's second-quarter outperformance was the integration of MyMedic, which contributed significantly to top-line growth. The acquisition pushed total sales up 16% year-over-year, demonstrating the immediate impact of the strategic expansion.

Excluding the impact of MyMedic, organic growth stood at a solid 8%, indicating that the core business is also performing well independently of the acquisition. This dual growth engine suggests that the company is successfully leveraging both its established product lines and new market opportunities.

Management is actively working to expand MyMedic's distribution beyond its direct-to-consumer channel into mass retail. This strategic shift aims to capture a broader customer base and increase brand visibility in traditional retail environments.

The integration of MyMedic has also positively impacted profitability, with gross margins expanding to 42.6% from 41.0% in the prior year period. This expansion indicates improved pricing power or cost efficiencies associated with the new product line.

CEO Johnsen highlighted that the integration is progressing well, with strategic efforts focused on scaling the brand across multiple channels. The company expects this expansion to continue driving revenue growth in the coming quarters.

What Is the Margin Recovery Outlook for Acme United?

Looking ahead, Acme United management provided optimistic guidance regarding its margin trajectory. CEO Johnsen indicated that margin recovery is expected to continue as the company navigates through current tariff pressures.

Specifically, the firm is actively replacing higher-tariff inventory with lower-cost stock throughout the remainder of the year. This strategic inventory management is expected to further bolster gross margins as the transition progresses.

The company anticipates strong profitability in the fourth quarter, supported by seasonal demand patterns and the continued benefits of lower-cost inventory. This outlook suggests that the margin expansion observed in Q2 is not an isolated event but part of a broader trend.

However, the transition from higher-tariff to lower-cost inventory is a process that will take time. Investors should monitor the pace of this transition and its impact on quarterly results as the year progresses.

What Are the Key Risks Facing Acme United Investors?

Despite the positive momentum, investors should monitor several headwinds that could impact future performance. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales, potentially compressing net income.

These elevated expenses are partly due to the costs associated with integrating MyMedic and expanding into new distribution channels. While these investments are necessary for long-term growth, they may weigh on short-term profitability.

Other significant risks include ongoing tariff and freight cost volatility, which could disrupt the company's cost management strategies. Currency headwinds also pose a risk, particularly as the company operates in multiple international markets.

Geographic performance has been uneven, with Canada lagging behind other regions. This disparity highlights the challenges of managing a global portfolio in a volatile economic environment.

The next earnings report is scheduled for October 27, 2026, covering the third quarter ended September 2026. Investors will be closely watching for updates on the MyMedic integration and the progress of the tariff mitigation strategy.